SCHEMBL25328534

SCHEMBL25328534

CC(C)(C)OC(=O)N1CC2(CC(COc3ccc(C(F)(F)F)cn3)C2)C1

nearest known ligand 0.48

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 7/20 0.48
CHRNA7 P36544 2/20 0.43
HCRTR1 O43613 8/20 0.42
EIF2AK4 Q9P2K8 1/20 0.41
CNR1 P21554 1/20 0.40
BCHE P06276 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30553324 1.00 LIPE (0.48) LIPECHRNA7HCRTR1EIF2AK4CNR1
SCHEMBL30327861 0.90 LIPE (0.49) LIPECHRNA7BCHE
SCHEMBL23850304 0.85 HSD11B1 (0.47) LIPE
SCHEMBL21606867 0.84 LIPE (0.62) LIPEBCHE
SCHEMBL29913011 0.84 LIPE (0.62) LIPEBCHE
SCHEMBL25252811 0.81 EIF2AK4 (0.39) EIF2AK4
SCHEMBL23850247 0.81 GPR119 (0.49) CHRNA7EIF2AK4
SCHEMBL29912781 0.80 LIPE (0.48) LIPECHRNA7HCRTR1BCHE
SCHEMBL22797267 0.79 OXTR (0.42)
SCHEMBL29427110 0.78 SCN9A (0.43) LIPEEIF2AK4BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 US disclosed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250099448-A1 HETEROCYCLIC COMPOUNDS OPRM1, CYP1A1, CYP3A4 LIPE 3975/4885CHRNA7 703/4885HCRTR1 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.